GlassScriptPhysician profile
Kimothy A Kane
NPI 1538753470
$4,074.55
in general payments reported to CMS, 2019-2025
20 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $699 · 2022: $895 · 2023: $1,007 · 2024: $1,096 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.66 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,280.23 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $729.05 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $544.03 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $489.81 | 2021-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $250.48 | 2021-2023 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $170.03 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $133.16 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $80.40 | 2023 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $73.73 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $72.60 | 2024-2025 | Fanapt |
| Noven Therapeutics, LLC | $57.40 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $45.53 | 2024-2025 | Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $31.17 | 2023-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $25.94 | 2022 | |
| Validus Pharmaceuticals LLC | $18.07 | 2023 | Equetro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $16.66 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.27 | 2022 | |
| Almatica Pharma LLC | $15.25 | 2023 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $12.95 | 2023 | Quviviq |
| Novo Nordisk INC | $12.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimothy Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.